Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362593886> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4362593886 endingPage "2668" @default.
- W4362593886 startingPage "2668" @default.
- W4362593886 abstract "Abstract Ovarian cancer (OVCA) is the most malignant gynecologic cancer. Despite the use of surgery and platinum-based chemotherapy, the 5-year survival rate is approximately 30% at the time of diagnosis. Cisplatin inhibits DNA synthesis by cross-linking DNA and then induces cell apoptosis. However, cisplatin resistance often causes treatment failure and tumor relapse in OVCA patients. To overcome the cisplatin resistance in OVCAs, we studied the mechanism of chemoresistance by a long non-coding RNA (lncRNA), TUG1 (taurine upregulated gene 1), which is associated with carcinogenesis and drug sensitivity in OVCAs. The expression level of TUG1 in cisplatin-resistant OVCA clinical samples is significantly higher than that of cisplatin-sensitive samples by public database. A depletion of TUG1 increased the sensitivity of OVCA cells to cisplatin together with upregulation of a set of miRNAs in vitro. We examined the targets of miRNAs and found that TUG1 depletion downregulates DNA polymerase eta (Polη) by upregulating the miRNAs. Polη is a major translesion DNA synthesis (TLS) DNA polymerase, which bypasses DNA lesions produced by DNA damaging agents and helps DNA replication. The expression level of Polη showed a positive correlation with that of TUG1 in OVCA clinical samples. Overexpression of Polη recovered cisplatin resistance in TUG1-depleted cells. Finally, cisplatin treatment combined with TUG1 depletion effectively inhibited tumor growth in xenograft mouse models, indicating the efficacy of TUG1 depletion in vivo. Our data provide a strong rationale for targeting TUG1 as a novel therapeutic approach to overcome cisplatin resistance in OVCA. Citation Format: Ryosuke Sonobe. Long non-cording RNA TUG1 promotes cisplatin resistance in ovarian cancer via DNA polymerase eta [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2668." @default.
- W4362593886 created "2023-04-06" @default.
- W4362593886 creator A5014220260 @default.
- W4362593886 date "2023-04-04" @default.
- W4362593886 modified "2023-09-25" @default.
- W4362593886 title "Abstract 2668: Long non-cording RNA TUG1 promotes cisplatin resistance in ovarian cancer via DNA polymerase eta" @default.
- W4362593886 doi "https://doi.org/10.1158/1538-7445.am2023-2668" @default.
- W4362593886 hasPublicationYear "2023" @default.
- W4362593886 type Work @default.
- W4362593886 citedByCount "0" @default.
- W4362593886 crossrefType "journal-article" @default.
- W4362593886 hasAuthorship W4362593886A5014220260 @default.
- W4362593886 hasConcept C104317684 @default.
- W4362593886 hasConcept C121608353 @default.
- W4362593886 hasConcept C134935766 @default.
- W4362593886 hasConcept C145059251 @default.
- W4362593886 hasConcept C153911025 @default.
- W4362593886 hasConcept C185592680 @default.
- W4362593886 hasConcept C2756471 @default.
- W4362593886 hasConcept C2776694085 @default.
- W4362593886 hasConcept C2778239845 @default.
- W4362593886 hasConcept C2780427987 @default.
- W4362593886 hasConcept C502942594 @default.
- W4362593886 hasConcept C54355233 @default.
- W4362593886 hasConcept C552990157 @default.
- W4362593886 hasConcept C55493867 @default.
- W4362593886 hasConcept C86803240 @default.
- W4362593886 hasConceptScore W4362593886C104317684 @default.
- W4362593886 hasConceptScore W4362593886C121608353 @default.
- W4362593886 hasConceptScore W4362593886C134935766 @default.
- W4362593886 hasConceptScore W4362593886C145059251 @default.
- W4362593886 hasConceptScore W4362593886C153911025 @default.
- W4362593886 hasConceptScore W4362593886C185592680 @default.
- W4362593886 hasConceptScore W4362593886C2756471 @default.
- W4362593886 hasConceptScore W4362593886C2776694085 @default.
- W4362593886 hasConceptScore W4362593886C2778239845 @default.
- W4362593886 hasConceptScore W4362593886C2780427987 @default.
- W4362593886 hasConceptScore W4362593886C502942594 @default.
- W4362593886 hasConceptScore W4362593886C54355233 @default.
- W4362593886 hasConceptScore W4362593886C552990157 @default.
- W4362593886 hasConceptScore W4362593886C55493867 @default.
- W4362593886 hasConceptScore W4362593886C86803240 @default.
- W4362593886 hasIssue "7_Supplement" @default.
- W4362593886 hasLocation W43625938861 @default.
- W4362593886 hasOpenAccess W4362593886 @default.
- W4362593886 hasPrimaryLocation W43625938861 @default.
- W4362593886 hasRelatedWork W1963617703 @default.
- W4362593886 hasRelatedWork W1992976746 @default.
- W4362593886 hasRelatedWork W2003624918 @default.
- W4362593886 hasRelatedWork W2014377706 @default.
- W4362593886 hasRelatedWork W2018026762 @default.
- W4362593886 hasRelatedWork W2064215138 @default.
- W4362593886 hasRelatedWork W2489762468 @default.
- W4362593886 hasRelatedWork W2808379594 @default.
- W4362593886 hasRelatedWork W2984941165 @default.
- W4362593886 hasRelatedWork W72424077 @default.
- W4362593886 hasVolume "83" @default.
- W4362593886 isParatext "false" @default.
- W4362593886 isRetracted "false" @default.
- W4362593886 workType "article" @default.